Andrew Mackie
Plus aucun poste en cours
Profil
Andrew Mackie formerly worked at Capsant Neurotechnologies Ltd., as Executive Chairman, Karus Therapeutics Ltd., as Non-Executive Director, Ergomed Plc, as Executive Director & Chief Business Officer from 2015 to 2018, Novartis, Inc., as Principal, Antisoma Research Ltd., as Head-Alliance Management, Sarossa Capital Ltd., as Head-Clinical Development, IP Group Plc, as Head-Life Sciences, MDS Co., Ltd., as Principal, Sanofi-Aventis Japan, as Principal, and Linklaters & Alliance.
Mr. Mackie received his undergraduate degree from Queen's University, graduate degree from the University of London, and Masters Business Admin degree from London Business School.
Anciens postes connus de Andrew Mackie
Sociétés | Poste | Fin |
---|---|---|
ERGOMED | Directeur/Membre du Conseil | 02/10/2018 |
Antisoma Research Ltd. | Corporate Officer/Principal | - |
IP GROUP PLC | Corporate Officer/Principal | - |
MDS Co., Ltd. | Corporate Officer/Principal | - |
Sarossa Capital Ltd.
Sarossa Capital Ltd. Financial ConglomeratesFinance Sarossa Capital Ltd. is an investment holding and management company. Its principal activity is investing in and growth and development of businesses which present opportunities for value creations. The company currently intends to indentify investment opportunities offering the potential to deliver a favorable return to shareholders over the medium term, primarily in the form of capital gain. The company was founded in 1988 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | - |
Formation de Andrew Mackie
University of London | Graduate Degree |
Queen's University | Undergraduate Degree |
London Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
ERGOMED | Commercial Services |
IP GROUP PLC | Commercial Services |
Entreprise privées | 7 |
---|---|
Capsant Neurotechnologies Ltd.
Capsant Neurotechnologies Ltd. Pharmaceuticals: MajorHealth Technology Capsant Neurotechnologies Ltd. provided pre-clinical assay services to the drug development industry. It offered in-vitro tissue based screening technologies based on ex-vivo tissues and reaggregated 3D systems. The firm significantly reduced the costs associated with pre-clinical drug development and shortening the overall decision process in the selection of lead candidates for clinical evaluation. The company was founded by Lars Eric Sundstrom, Ashley Ker Pringle and John Edward Chad on June 21, 2002 and was headquartered in Gray's Inn, the United Kingdom. | Health Technology |
Karus Therapeutics Ltd.
Karus Therapeutics Ltd. BiotechnologyHealth Technology Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom. | Health Technology |
Novartis, Inc.
Novartis, Inc. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis, Inc. is a company based in San Francisco. | Health Technology |
Sanofi-Aventis Japan | |
Sarossa Capital Ltd.
Sarossa Capital Ltd. Financial ConglomeratesFinance Sarossa Capital Ltd. is an investment holding and management company. Its principal activity is investing in and growth and development of businesses which present opportunities for value creations. The company currently intends to indentify investment opportunities offering the potential to deliver a favorable return to shareholders over the medium term, primarily in the form of capital gain. The company was founded in 1988 and is headquartered in London, the United Kingdom. | Finance |
MDS Co., Ltd. | Distribution Services |
Antisoma Research Ltd. |